Thyroid's secretory capacity

Thyroid's secretory capacity
Synonyms	SPINA-GT, GT, T4 output, thyroid hormone output, thyroid's incretory capacity
Reference range	1.41–8.67 pmol/s
Test of	Maximum amount of T4 produced by the thyroid in one second
LOINC	82368-2

Thyroid's secretory capacity (G_T, also referred to as thyroid's incretory capacity, maximum thyroid hormone output, T4 output or, if calculated from serum levels of thyrotropin and thyroxine, as SPINA-GT) is the maximum stimulated amount of thyroxine that the thyroid can produce in a given time-unit (e.g. one second).

How to determine GT

Experimentally, GT can be determined by stimulating the thyroid with a high thyrotropin concentration (e.g. by means of rhTSH, i.e. recombinant human thyrotropin) and measuring its output in terms of T4 production, or by measuring the serum concentration of protein-bound iodine-131 after administration of radioiodine.

In vivo, GT can also be estimated from equilibrium levels of TSH and T4 or free T4. In this case it is calculated with

<math>\hat G_T = {{\beta _T (D_T + [TSH])(1 + K_{41} [TBG] + K_{42} [TBPA])[FT_4 ]} \over {\alpha _T [TSH]}}</math>

or

<math>\hat G_T = {{\beta _T (D_T + [TSH])[TT_4 ]} \over {\alpha _T [TSH]}}</math>

<math>\hat G_T </math>: Theoretical (apparent) secretory capacity (SPINA-GT)
<math>\alpha _T</math>: Dilution factor for T4 (reciprocal of apparent volume of distribution, 0.1 l⁻¹)
<math>\beta _T</math>: Clearance exponent for T4 (1.1e-6 sec⁻¹)
K₄₁: Dissociation constant T4-TBG (2e10 l/mol)
K₄₂: Dissociation constant T4-TBPA (2e8 l/mol)
D_T: EC₅₀ for TSH (2.75 mU/l)

Specific secretory capacity

The ratio of SPINA-GT and thyroid volume V_T (as determined e.g. by ultrasonography)

<math>\hat{G}_{TS}=\frac{\hat{G}_{T}}{{V}_{T}}</math>,

i.e.

<math>\hat{G}_{TS}=\frac{\beta_{T}(D_{T}+[TSH])(1+K_{41}[TBG]+K_{ 42 }[TBPA])[FT_{4}]}{{\alpha_{T}[TSH]{V}_{T}}}</math>

or

<math>\hat{G}_{TS}=\frac{{{\beta_{T}(D_{T}+[TSH])[TT_{4}]}}}{{\alpha_{T}[TSH]{V}_{T}}}</math>

is referred to as specific thyroid capacity (SPINA-GTs).

Reference Range

Lower limit	Upper limit	Unit
1.41	8.67	pmol/s

The equations and their parameters are calibrated for adult humans with a body mass of 70 kg and a plasma volume of ca. 2.5 l.

Clinical significance

Validity

SPINA-GT is elevated in primary hyperthyroidism and reduced in both primary hypothyroidism and untreated autoimmune thyroiditis. It has been observed to correlate (with positive direction) to resting energy expenditure and thyroid volume, and (with negative direction) to thyroid autoantibody titres, which reflect organ destruction due to autoimmunity. Elevated SPINA-GT in Graves's disease is reversible with antithyroid treatment. While SPINA-GT is significantly altered in primary thyroid disorders, it is insensitive to disorders of secondary nature (e.g. pure pituitary diseases).

Reliability

In silico experiments with Monte Carlo simulations demonstrated that both SPINA-GT and SPINA-GD can be estimated with sufficient reliability, even if laboratory assays have limited accuracy. This was confirmed by longitudinal in vivo studies that showed that GT has lower intraindividual variation (i.e. higher reliability) than TSH, FT4 or FT3.

Clinical utility

In clinical trials SPINA-GT was significantly elevated in patients suffering from Graves' disease and toxic adenoma compared to normal subjects. It is also elevated in diffuse and nodular goiters, and reduced in untreated autoimmune thyroiditis. In patients with toxic adenoma it has higher specificity and positive likelihood ratio for diagnosis of thyrotoxicosis than serum concentrations of thyrotropin, free T4 or free T3. GT's specificity is also high in thyroid disorders of secondary or tertiary origin.

Pathophysiological and therapeutic implications

Correlation of SPINA-GT with creatinine clearance suggested a negative influence of uremic toxins on thyroid biology. In the initial phase of major non-thyroidal illness syndrome (NTIS) SPINA-GT may be temporarily elevated. In chronic NTIS as well as in certain non-critical chronic diseases, e.g. chronic fatigue syndrome or asthma SPINA-GT ist slightly reduced.

In women, therapy with Metformin results in increased SPINA-GT, in parallel to improved insulin sensitivity. This observation was reproducible in men with hypogonadism, but not in men with normal testosterone concentrations, so that the described effect seems to depend on androgen levels. In hyperthyroid men both SPINA-GT and SPINA-GD negatively correlate to erectile function, intercourse satisfaction, orgasmic function and sexual desire. Likewise, in women suffering from thyrotoxicosis elevated thyroid's secretory capacity predicts depression and sexual dysfunction. Conversely, in androgen-deficient men with concomitant autoimmune thyroiditis, substitution therapy with testosterone leads to a decrease in thyroid autoantibody titres and an increase in SPINA-GT.

In patients with autoimmune thyroiditis a gluten-free diet results in increased SPINA-GT (in parallel to sinking autoantibody titres). Statin therapy has the same effect, but only if supply with vitamin D is sufficient. Accordingly, substitution therapy with 25-hydroxyvitamin D leads to rising secretory capacity. This effect is potentiated by substitution therapy with selenomethionine.

On the other hand, men treated with spironolactone are faced with decreasing SPINA-GT (in addition to rising thyroid antibody titres). It has, therefore, been concluded that spironolactone may aggravate thyroid autoimmunity in men.

Specific secretory capacity (SPINA-GTs) is reduced in obesity and autoimmune thyroiditis.

See also

• Thyroid function tests
• Sum activity of peripheral deiodinases
• Jostel's TSH index
• Thyrotroph Thyroid Hormone Sensitivity Index
• SimThyr

External links

• SPINA Thyr: Open source software for calculating GT and GD
• Package "SPINA" for the statistical environment R